Identification and Functional Characterization of the Human Glutathione S-Transferase P1 Gene as a Novel Transcriptional Target of the p53 Tumor Suppressor Gene
- 1 May 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 6 (5), 843-850
- https://doi.org/10.1158/1541-7786.mcr-07-2105
Abstract
The glutathione S-transferase P1 (GSTP1) is involved in multiple cellular functions, including phase II metabolism, stress response, signaling, and apoptosis. The mechanisms underlying the significantly high GSTP1 expression in many human tumors are, however, currently not well understood. We report here that the GSTP1 gene is a heretofore unrecognized downstream transcriptional target of the tumor suppressor p53. We identified a p53-binding motif comprising two consecutive half-sites located in intron 4 of the GSTP1 gene and is highly homologous to consensus p53-binding motifs in other p53-responsive genes. Using a combination of electrophoretic mobility shift assay and DNase I footprinting analyses, we showed that wild-type p53 protein binds to the GSTP1 p53 motif and luciferase reporter assays showed the motif to be transcriptionally functional in human tumor cells. In a temperature-sensitive p53-mutant cells, levels of both p21/WAF1 and GSTP1 gene transcripts increased time dependently when cells were switched from the inactive mutant state to the wild-type p53 state. Small interfering RNA–mediated reduction of p53 expression resulted in a specific decrease in GSTP1 expression and in tumor cells with mutated p53; adenovirally mediated expression of wild-type p53 increased GSTP1 expression significantly. In a panel of early-passage brain tumor cultures from patients, high levels of GSTP1 transcripts and protein were associated with wild-type p53 and, conversely, low GSTP1 levels with mutant p53. p53 expression knockdown by small interfering RNA increased cisplatin sensitivity. The ability of wild-type p53 to transcriptionally activate the human GSTP1 gene defines a novel mechanism of protecting the genome and, potentially, of tumor drug resistance. (Mol Cancer Res 2008;6(5):843–50)Keywords
This publication has 46 references indexed in Scilit:
- In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant GliomasClinical Cancer Research, 2006
- Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathwayCancer Cell, 2005
- Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicinCancer Gene Therapy, 2004
- Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating PeptidePLoS Biology, 2004
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB‐1 with the GSTP1 CRE: A novel mechanism of cellular GSTP1 gene regulationJournal of Cellular Biochemistry, 2002
- Prolonged Wild-Type p53 Protein Accumulation and Cisplatin ResistanceBiochemical and Biophysical Research Communications, 2001
- DNA methyltransferase levels and altered CpG methylation in the total genome and in the GSTP1 gene in human glioma cells transfected with sense and antisense DNA methyltransferase cDNAJournal of Cellular Biochemistry, 2000
- Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 functionJournal of Neurosurgery, 1998
- Sp1-mediated Transcriptional Activation of the Human Pi Class Glutathione S-Transferase PromoterPublished by Elsevier BV ,1996